MA51015A - Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci - Google Patents
Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ciInfo
- Publication number
- MA51015A MA51015A MA051015A MA51015A MA51015A MA 51015 A MA51015 A MA 51015A MA 051015 A MA051015 A MA 051015A MA 51015 A MA51015 A MA 51015A MA 51015 A MA51015 A MA 51015A
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- prevention
- treatment
- heart failure
- adrenergic receptor
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 title 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595133P | 2017-12-06 | 2017-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51015A true MA51015A (fr) | 2021-04-21 |
Family
ID=64744985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051015A MA51015A (fr) | 2017-12-06 | 2018-12-06 | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11339172B2 (https=) |
| EP (1) | EP3720858B1 (https=) |
| JP (1) | JP7357617B2 (https=) |
| CN (1) | CN111699189B (https=) |
| AR (1) | AR114156A1 (https=) |
| ES (1) | ES2953576T3 (https=) |
| MA (1) | MA51015A (https=) |
| TW (1) | TWI822713B (https=) |
| WO (1) | WO2019113359A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| CN111699189B (zh) * | 2017-12-06 | 2025-02-18 | 艾尼纳制药公司 | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20250127773A1 (en) * | 2021-08-09 | 2025-04-24 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| JP2024532227A (ja) | 2021-08-26 | 2024-09-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腎嚢胞性疾患および心腎症候群の処置または予防のためのベータ３アドレナリン作動性受容体のモジュレーター |
| US20240409548A1 (en) | 2021-10-06 | 2024-12-12 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
| JP4782342B2 (ja) | 1999-12-17 | 2011-09-28 | サノフィ−アベンティス | フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| US20080255134A1 (en) | 2004-11-30 | 2008-10-16 | Artesian Therapeutics, Inc. | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase |
| PT3206678T (pt) | 2014-10-14 | 2020-03-23 | Sculpt B V | Escultura corporal |
| MA44037B1 (fr) * | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| CN111699189B (zh) | 2017-12-06 | 2025-02-18 | 艾尼纳制药公司 | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 |
-
2018
- 2018-12-06 CN CN201880088219.8A patent/CN111699189B/zh active Active
- 2018-12-06 WO PCT/US2018/064316 patent/WO2019113359A1/en not_active Ceased
- 2018-12-06 TW TW107143855A patent/TWI822713B/zh active
- 2018-12-06 MA MA051015A patent/MA51015A/fr unknown
- 2018-12-06 EP EP18822236.8A patent/EP3720858B1/en active Active
- 2018-12-06 JP JP2020530969A patent/JP7357617B2/ja active Active
- 2018-12-06 ES ES18822236T patent/ES2953576T3/es active Active
- 2018-12-06 US US16/769,507 patent/US11339172B2/en active Active
- 2018-12-06 AR ARP180103577A patent/AR114156A1/es unknown
-
2022
- 2022-04-22 US US17/726,807 patent/US11987588B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3720858C0 (en) | 2023-06-07 |
| US11987588B2 (en) | 2024-05-21 |
| CN111699189A (zh) | 2020-09-22 |
| ES2953576T3 (es) | 2023-11-14 |
| US11339172B2 (en) | 2022-05-24 |
| JP2021505598A (ja) | 2021-02-18 |
| CN111699189B (zh) | 2025-02-18 |
| AR114156A1 (es) | 2020-07-29 |
| US20200385395A1 (en) | 2020-12-10 |
| WO2019113359A1 (en) | 2019-06-13 |
| TW201925206A (zh) | 2019-07-01 |
| EP3720858A1 (en) | 2020-10-14 |
| US20220396579A1 (en) | 2022-12-15 |
| JP7357617B2 (ja) | 2023-10-06 |
| EP3720858B1 (en) | 2023-06-07 |
| TWI822713B (zh) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51015A (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de l'insuffisance cardiaque et de troubles associés à celle-ci | |
| MA50417A (fr) | Procédés d'utilisation d'inhibiteurs de l'ehmt2 dans le traitement ou la prévention de troubles du sang | |
| EP3707275A4 (en) | DOSAGE AND VARIETY RECOMMENDATIONS FOR THE TREATMENT OF DISEASES USING CANNABIS | |
| EP3755805A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL | |
| FR24C1010I2 (fr) | Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux | |
| EP3861121A4 (en) | RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS | |
| EP3448389A4 (en) | CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER | |
| EP3471780A4 (en) | TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT | |
| EP3405215A4 (en) | METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| EP3692171A4 (en) | USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS | |
| MA44119A (fr) | Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale | |
| EP4054687A4 (en) | Breathing assistance apparatuses and/or components thereof and/or uses thereof | |
| EP3639833A4 (en) | AGENTS FOR THE PREVENTION OR TREATMENT OF FAT RELATED DISEASES AND INFLAMMATION | |
| EP3810142A4 (en) | ANTIRETROVIRAL THERAPIES AND REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP3773605A4 (en) | Hinges 1 and/or 4 modified dystrophins for dystrophinopathy therapy | |
| EP3743091A4 (en) | PROCEDURES AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| EP3664795A4 (en) | CANNABIS AND DERIVATIVES THEREOF IN THE TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED WITH DENTAL MARSH AND BONE REGENERATION ASSOCIATED WITH JAWBONE DEFECTS | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| EP3876967A4 (en) | Therapeutic microbiota for the treatment and/or prevention of dysbiosis | |
| HRP20260324T1 (hr) | Guselkumab za upotrebu u liječenju crohnove bolesti uz režim doziranja | |
| EP3856168A4 (en) | COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES | |
| EP3348643A4 (en) | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS | |
| EP3654961A4 (en) | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN WITH CAPSAICIN |